ImpriMed secures $10 million in a Series A2 bridge round, with NAVER D2SF as a key investor. This funding will help ImpriMed advance its AI-driven precision medicine solutions.
Amount Raised
$10 Million
Round Type
Series A
Mountain ViewBiotechnologyHealth CareArtificial IntelligenceMedicalHealth DiagnosticsInvestors
Description
NAVER D2SF has invested in ImpriMed, joining the company's $10 million Series A2 bridge round. ImpriMed focuses on AI-driven precision medicine, leveraging data to enhance personalized treatment decisions. The funding will support its efforts to commercialize products and establish partnerships in North America. ImpriMed aims for FDA clearance and CLIA certification by early 2027.
Quick answer
ImpriMed raised $10 Million in a Series A round, dated September 18, 2026. Investors: Naver D2 Sf. ImpriMed is based in Mountain View, California, United States.
- How much did ImpriMed raise?
- ImpriMed raised $10 Million in a Series A round on September 18, 2026.
- Who invested in ImpriMed?
- Naver D2 Sf is named as investors in this round.
- What does ImpriMed do?
- ImpriMed provides cutting-edge personalized medicine easily accessible for pets with blood cancer diseases.
- Where is ImpriMed based and how big is it?
- ImpriMed is based in Mountain View, California, United States. Fundz records about 46 employees.
- Who are the decision-makers at ImpriMed?
- Fundz holds 1 contact at ImpriMed. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical and Health Diagnostics around the same time
Companies in the same sectors as ImpriMed that raised within 45 days of this round, from Fundz verified event records.
- BioStack raised $9.5M (Seed) on October 22, 2026.
- Coherence Neuro raised $45M (Series A) on October 22, 2026.
- AIBORN Ltd raised an undisclosed amount on October 5, 2026.
- UltraSight raised $24M (Series B) on September 23, 2026.
- Cascader raised an undisclosed amount (Seed) on September 23, 2026.
- LymeLess Health raised an undisclosed amount (Seed) on August 22, 2026.
Who to call at ImpriMed, and when
A new round usually means ImpriMed is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day ImpriMed raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at ImpriMed, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at ImpriMed. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ImpriMed raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansImpriMed raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.